About EmbarkNeuro

EmbarkNeuro, formerly known as Ancora Bio, is focused on bringing important new personalized treatments to patients with mental health disorders. Rates of major depression are rapidly rising, much of this attributable to the dramatic increase in stress brought on by the COVID-19 pandemic. The company is identifying depressed individuals with a potential biomarker linked to the stress response system (elevated cortisol) and developing ANC-501 as a new treatment specifically for these patients.